LY6K — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL24030236	1.00	2/20
SCHEMBL22401407	0.94	2/20
SCHEMBL24030232	0.67	1/20
SCHEMBL19326754	0.57	1/20
SCHEMBL20533126	0.57	1/20
SCHEMBL13528559	0.55	1/20
SCHEMBL13529543	0.55	1/20
SCHEMBL19326743	0.55	1/20
SCHEMBL526197	0.54	1/20
SCHEMBL13528030	0.54	1/20
SCHEMBL18391011	0.54	1/20
SCHEMBL19326744	0.53	1/20
SCHEMBL2759559	0.53	1/20
SCHEMBL13531050	0.53	1/20
SCHEMBL4042891	0.53	1/20
SCHEMBL17489872	0.53	1/20
SCHEMBL20533247	0.53	1/20
SCHEMBL10191057	0.53	1/20
SCHEMBL18413450	0.53	1/20
SCHEMBL21801755	0.53	1/20

Clinical trials — most relevant to LY6K by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Evaluation of Cytokine-induced Killer (CIK) Cells as Therapy or Adjuvant Treatment for Advanced HCC	PHASE3	UNKNOWN
Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders	PHASE2	COMPLETED
Gene Transfer Clinical Trial to Deliver rAAVrh74.MCK.GALGT2 for Duchenne Muscular Dystrophy	PHASE1/PHASE2	COMPLETED
Infusion of Donor Derived Cytokine Induced Killer (CIK) Cells in Hematological Patients Relapsed After Haploidentical Stem Cell Transplant	PHASE1/PHASE2	UNKNOWN
CIK-Cells in Relapsing Patients With Acute Leukemia or Myelodysplastic Syndromes After SCT.	PHASE1/PHASE2	UNKNOWN
Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies	PHASE1/PHASE2	COMPLETED
Cytokine-induced Killer Study for Patients With Stage II Melanoma	PHASE2	NOT_YET_RECRUITING
Treatment of CIK for Patients With Refractory Non-Hodgkin Lymphoma	PHASE2	NOT_YET_RECRUITING
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
Exploratory Regimen of Basiliximab for Treatment of Pulmonary Cytokine Storm in SARS-CoV-2 Hospitalized Adult Patients	PHASE2	UNKNOWN
Safety Study of Multiple Peptide Vaccine to Esophageal Cancer	PHASE1	COMPLETED
Peptide Vaccination in Treating Patients With Esophageal Cancer	PHASE1	UNKNOWN
HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection	PHASE1	WITHDRAWN
Tolerability and Safety of HF1K16 Injection in Patients With Refractory Solid Tumors	PHASE1	UNKNOWN
A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)	PHASE1	COMPLETED
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies	PHASE1	COMPLETED
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED
Preconditioning Chemotherapy Combination With Cytokine Induced Killer Cell (CIK) Immunotherapy	nan	UNKNOWN
TIGIT in Patients With Chronic Myeloid Leukemia	nan	UNKNOWN
Pharmacogenomics of Interferon and Ribavirin Treatment in Patients With Chronic Hepatitis C Virus Infection	nan	UNKNOWN
Improving the Diagnosis of Common Variable Immune Deficiency	nan	COMPLETED
Implication of CCR4-NOT Complex Subunit 7 Expression in Natural Killer Cell Resistance in Metastatic Breast Cancer	nan	COMPLETED
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia	nan	UNKNOWN
Allogeneic HCT Using Conditioning Regimen of BuFluATG for AML CR1	nan	COMPLETED
RT201(Tumor Antigen-specific Macrophage Tumor Vaccine)	nan	UNKNOWN
Mobilising Tumour and Immune Cells Via Exercise in Chronic Lymphocytic Leukaemia	nan	COMPLETED
Infant Immune Response to Bacterial Infection	nan	COMPLETED
Expression of CD19 Complex in Lymphoproliferative Disorders	nan	UNKNOWN
Applying Systems Immunology to the Search for Personalized Biomarkers of Clinical Efficacy	nan	COMPLETED
Evaluating the Genetics and Immunology of Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis (PFAPA) Syndrome and Other Tonsil Disorders	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a LY6K binder may also engage these)

Protein	Name	Similarity
Q8NI32	—	0.990	Q8NI32 →
Q9CWP4	—	0.989	Q9CWP4 →
Q924B5	—	0.987	Q924B5 →
Q9D7Z7	—	0.985	Q9D7Z7 →
Q9D7F2	—	0.984	Q9D7F2 →
H3BJG9	—	0.983	H3BJG9 →
H2LID1	—	0.982	H2LID1 →
Q9JMI7	—	0.982	Q9JMI7 →
Q6AXW8	—	0.981	Q6AXW8 →
Q91YK8	—	0.981	Q91YK8 →
Q32PB3	—	0.980	Q32PB3 →
Q9GK77	—	0.980	Q9GK77 →
O55006	—	0.979	O55006 →
O95274	—	0.979	O95274 →
Q0VCB1	—	0.979	Q0VCB1 →
Q9DA16	—	0.979	Q9DA16 →
Q99445	—	0.979	Q99445 →
Q80ZQ0	—	0.978	Q80ZQ0 →
Q6UX82	—	0.978	Q6UX82 →
P27274	—	0.978	P27274 →
O55186	—	0.978	O55186 →
P0DPQ9	—	0.978	P0DPQ9 →
P13385	—	0.978	P13385 →
Q06186	—	0.977	Q06186 →
Q8K1T4	—	0.977	Q8K1T4 →
O43278	—	0.977	O43278 →
Q8NDX9	—	0.977	Q8NDX9 →
B2BS84	—	0.976	B2BS84 →
Q66H42	—	0.976	Q66H42 →
Q9GK80	—	0.976	Q9GK80 →